Novavax Delays Phase 3 COVID-19 Vaccine Trial Again in the U.S.
[Asia Economy Reporter Kiho Sung] Novavax has once again postponed the Phase 3 clinical trial of its novel coronavirus disease (COVID-19) vaccine candidate in the United States.
Novavax had originally planned to start the clinical trial in the U.S. in mid-last month but postponed it once due to issues with expanding vaccine production. This is the second time the trial has been delayed.
Hot Picks Today
Cerebras Soars 70% on IPO Debut: Is Nvidia's Reign Ending as a New AI Semiconductor Power Emerges?
- Russia and Ukraine Exchange 205 Prisoners Each... "First Stage of 1,000-for-1,000 Swap"
- "Multi-Million Won Bonuses, Life Is Sweet"—Even Employee Reactions... SK hynix Overtakes Samsung to Claim No. 1 Spot
- "It Costs 100,000 Won for Two Hours"...No Place for Kids to Play if Parents Can't Afford It
- Japanese Teacher Dismissed for Obscene Acts Involving Third-Grade Girl's Water Bottle
Novavax expects to begin the clinical trial in the U.S. in a few weeks.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
